Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis to reveal new data on blood pressure drug

Novartis to reveal new data on blood pressure drug

15th May 2006

Novartis may reveal the details of a new study for its forthcoming blood pressure drug, Rasilez at the American Society of Hypertension.

According to Reuters reports, the data is likely to be positive and will reinforce speculation that Rasilez could be a big seller for the Swiss company, which could earn $1 billion (527 million pounds) in sales by 2011.

Novartis filed Rasilez for approval with the FDA during April, both as a therapy in itself and in combination with other hypertension drugs. The drug inhibits the production of renin, an enzyme which causes the production of chemicals in the liver that cause the constriction of blood vessels, resulting in higher blood pressure.

The company says it will be the first daily oral renin inhibitor and added that the drug demonstrated “significant” lowering of blood pressure in phase II trials.

In other Novartis-related news, the company’s generics division, Sandoz, has said it intends to launch an assault on the biotechnology market with the release of new generic versions of biotechnology drugs. Sandoz chief executive, Andreas Rummelt, told the Financial Times: “We have five further drugs in the pipeline at different stages of development.”

track© Adfero Ltd

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.